CSI Market
Sign In | Register

Casi Pharmaceuticals inc (CASIF) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access CASIF Annual Income Statement →
From Casi Pharmaceuticals inc through Dec 31 2024, changes in Dec 31 2025's revenue and cost structure provide insight into profitability trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CASIF/income-statements
https://api.csimarket.com/api/v1/companies/CASIF/fundamentals
https://api.csimarket.com/api/v1/companies/CASIF/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
Q4 2025 		0 0 0 (Dec 31 2024)
Revenues
Sales of Products0.00
Total Revenue20.71
Costs & Expenses
Cost of Goods and Services Sold10.64
Gross Profit10.08
Selling, Administration, Marketing18.34
Research and Development Expense6.31
Restructuring, Accretion & Impairment Charges0.00
Other Operating Expense / -Income30.43
Total operating costs including COS65.72
Operating income / -loss-45.01
Interest Expense0.84
Net Interest (-)Expense / Income-0.84
Loss (Income) from Equity Method Investments-2.19
Foreign Currency Transaction Gain (Loss), before Tax2.16
Other loss / -income0.01
Total costs & expenses66.58
Income & Taxes
Income / -loss before income taxes-45.87
Income after income taxes-48.06
Net income / -loss of other equity-2.19
Income / -loss from continuing operations-48.06
Net income / -loss-48.06
Income / -loss to shareholder-48.06
EBIT-45.03
EBITD-43.80
EBITDA-43.77
Earnings Per Share
Basic EPS (excl. extra items)-2.59
Basic Net EPS-2.59
Basic shares outstanding (Mill. of Units)18.54
Diluted Net EPS-2.59
Diluted average shares (Mill. of Units)18.54
4 historic quarters locked

Sign in to unlock the full Casi Pharmaceuticals inc income statement history.

Sign In Create Free Account

About CASIF Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI